GWOXI Stem Cell, since establishing its Stem Cell R&D Center in 2011, has been guided by the vision of becoming a pioneer in stem cell therapies. We are committed to developing stem cell technologies to address unmet medical needs. From research and manufacturing to clinical translation, we have steadily built a solid foundation for cell therapy.
GWOXI has successfully established a medical-grade platform for manufacturing stem cell preparations and has developed a number of key patents and core technologies. These include our stem cell activation technology, Nigiro-Med®, as well as medical-grade stem cell storage and clinical cell product quality inspection services. To date, we have advanced four new stem cell drugs into the clinical trial stage, demonstrating GWOXI's leading position and practical capabilities in the field of regenerative medicine R&D.
Based on the requirements of stem cell new drug development, GWOXI provides a full suite of cell technology services that comply with the current operational regulations for cell therapy set by the Ministry of Health and Welfare (MOHW). These services cover the entire process, from cell tissue screening and processing to final distribution.
All hardware and software within the facility have undergone DQ, IQ, OQ, PQ validation and multiple audits to ensure product safety and consistency. Furthermore, GWOXI has established a PIC/S GMP-compliant cell therapy drug facility in the Hsinchu Biomedical Science Park. This facility is designed to scale up production, moving from a liter-level process to full-scale manufacturing and strengthening the company’s strategic position within the cell therapy industry chain.
Upholding our core values of "Innovation, Excellence, and Responsibility," GWOXI continues to collaborate with industry, government, academia, research, and medical institutions to develop cell therapy technologies. Our goal is to promote the launch of cell therapy products and seek international collaboration opportunities.
Looking ahead, we will continue to enhance our technological innovation and strengthen our industry presence. With a strategy to establish a firm foundation in Taiwan while expanding internationally, we will progressively enter the global regenerative medicine market. By doing so, we aim to achieve our goal of becoming a pioneer in stem cell new drugs and contribute to the prosperity of the entire regenerative medicine field.
Chairman of the Board
- Beyond our unique technology platform, professional R&D team, and stable partnerships, we are actively strengthening our core stem cell technologies and integrated platforms. By leveraging diversified services and pragmatic strategies, we're building a global presence and creating a differentiated advantage in the cell therapy industry.This approach solidifies GWOXI's position as a leader in the stem cell field.
General Manager
- GWOXI constantly monitors market changes and proactively established its strategic position in the cell therapy industry. The company is dedicated to developing stem cell new drugs with high market share, with four new drugs already in the clinical trial stage.Furthermore, in the highly competitive biotech industry, GWOXI has adopted a dual-track operational strategy. By simultaneously developing innovative technologies and providing a wide range of technical services, we are pursuing a dual-track growth in both profitability and innovation.
Chief Technology Officer (CTO)
- GWOXI Stem Cell's biggest breakthrough in recent years has been mastering the pharmaceutical technology of stem cells. Through the development of our patented processes, we are now able to unlock the unlimited application potential of stem cells.
Press Releases
Press Releases-
04202507Press ReleasesGWOXI Stem Cell Enters Japan to Expand International Regenerative Medicine Business, Pushing to Internationalize Adipose Stem Ce -
16202506Press ReleasesGWOXI Stem Cell Makes a Preemptive Strategic Move to Address the Dual Challenges of Population Aging and Younger-Onset Stroke. -
13202505Press ReleasesGWOXI's New Stem Cell Drug for Osteoarthritis Approved to Start a Phase III Clinical Trial in Taiwan.